No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

Antoinette Hollestelle; FH van der Baan; A Berchuck; SE Johnatty; KK Aben; BA Agnarsson; K Aittomaki; E Alducci; IL Andrulis; H Anton-Culver; NN Antonenkova; AC Antoniou; C Apicella; V Arndt; N Arnold; BK Arun; B Arver; A Ashworth; L Baglietto; R Balleine; EV Bandera; D Barrowdale; YT Bean; L Beckmann; MW Beckmann; J Benitez; A Berger; R Berger; B Beuselinck; M Bisogna; L Bjorge; C Blomqvist; NV Bogdanova; A Bojesen; SE Bojesen; MK Bolla; B Bonanni; JS Brand; H Brauch; H Brenner; L Brinton; A Brooks-Wilson; F Bruinsma; J Brunet; T Bruning; A Budzilowska; CH Bunker; B Burwinkel; R Butzow; SS Buys; MA Caligo; I Campbell; J Carter; J Chang-Claude; SJ Chanock; KBM Claes; Margriet Collee; LS Cook; FJ Couch; A Cox; D Cramer; SS Cross; JM Cunningham; C Cybulski; K Czene; F Damiola; A Dansonka-Mieszkowska; H Darabi; M de la Hoya; A Defazio; J Dennis; P Devilee; EM Dicks; O Diez; JA Doherty; SM Domchek; CM Dorfling; T Dork; ID Silva; A (Andreas) du Bois; M Dumont; AM Dunning; M (Mercedes) Duran; DF Easton; D Eccles; RP Edwards; H Ehrencrona; B Ejlertsen; AB Ekici; SD Ellis; C Engel; M Eriksson; PA Fasching; L Feliubadalo; J Figueroa; D Flesch-Janys; O Fletcher; A Fontaine; S Fortuzzi; F Fostira; BL Fridley; T Friebel; E Friedman; G Friel; D Frost; J Garber; M Garcia-Closas; SA Gayther; A Gentry-Maharaj; AM Gerdes; GG Giles; R Glasspool; G Glendon; AK Godwin; MT Goodman; M Gore; MH Greene; M Grip; J Gronwald; DG Kaulich; P Guenel; SR Guzman; L Haeberle; CA Haiman; P Hall; SL Halverson; U Hamann; TVO Hansen; P Harter; JM Hartikainen; S Healey; A Hein; F Heitz; BE Henderson; J Herzog; MAT Hildebrandt; CK Bogdan; E Hogdall; FBL Hogervorst; JL Hopper; K Humphreys; T Huzarski; EN Imyanitov; C Isaacs; A Jakubowska; R Janavicius; K Jaworska; A Jensen; UB Jensen; N Johnson; A Jukkola-Vuorinen; M Kabisch; BY Karlan; V Kataja; N Kauff; LE Kelemen; MJ Kerin; LA Kiemeney; SK Kjaer; JA Knight; JP Knol-Bout; I Konstantopoulou; VM Kosma; C Krakstad; V Kristensen; KB Kuchenbaecker; J Kupryjanczyk; Y Laitman; D Lambrechts; S Lambrechts; MC Larson; A Lasa; P Laurent-Puig; C (Conxi) Lazaro; ND Le; L Le Marchand; A Leminen; J Lester; DA Levine; JM Li; D Liang; A Lindblom; N Lindor; J Lissowska; JR Long; KH Lu; J Lubinski; L Lundvall; G Lurie; PL Mai; A Mannermaa; S Margolin; F Mariette; F Marme; John Martens; LFAG Massuger; C Maugard; S Mazoyer; L McGuffog; V McGuire; C McLean; L McNeish; A Meindi; F Menegaux; P Menendez; J Menkiszak; U Menon; AR Mensenkamp; N Miller; RL Milne; F Modugno; M Montagna; KB Moysich; H Muller; AM Mulligan; TA Muranen; SA Narod; KL Nathanson; RB Ness; SL Neuhausen; H Nevanlinna; P Neven; FC Nielsen; SF Nielsen; BG Nordestgaard; RL Nussbaum; K Odunsi; K Offit; E Olah; OI Olopade; JE Olson; SH Olson; JC Oosterwijk; I Orlow; N Orr; S Orsulic; A Osorio; L Ottini; J Paul; CL Pearce; IS Pedersen; B Peissel; T Pejovic; LM Pelttari; J Perkins; J Permuth-Wey; P Peterlongo; J Peto; CM Phelan; KA Phillips; M Piedmonte; MC Pike; R Platte; J Plisiecka-Halasa; EM Poole; B (Bruce) Poppe; K Pylkas; P Radice; SJ Ramus; TR Rebbeck; MWR Reed; G Rennert; HA Risch; M Robson; GC Rodriguez; A Romero; MA Rossing; JH Rothstein; A Rudolph; I Runnebaum; R Salani; HB Salvesen; EJ Sawyer; JM Schildkraut; MK (Marjanka) Schmidt; RK Schmutzler; A Schneeweiss; MJ Schoemaker; MG Schrauder; F Schumacher; I Schwaab; G Scuvera; TA Sellers; G Severi; Caroline Seynaeve; M Shah; M Shrubsole; N Siddiqui; W Sieh; J Simard; CF Singer; OM Sinilnikova; D Smeets; C Sohn; M Soller; H Song; P Soucy; MC Southey; C Stegmaier; D Stoppa-Lyonnet; L Sucheston; A Swerdlow; IL Tangen; MK Tea; MR Teixeira; KL Terry; MB Terry; Marga Thomassen; PJ Thompson; L Tihomirova; M Tischkowitz; AE Toland; RAEM Tollenaar; I Tomlinson; D Torres; T Truong; H Tsimiklis; N Tung; SS Tworoger; JP Tyrer; CM Vachon; LJ (Laura) van 't Veer; AM van Altena; CJ van Asperen; D van den Berg; Ans van den Ouweland; HC van Doom; E Van Nieuwenhuysen; EJ van Rensburg; I Vergote; S Verhoef; RA Vierkant; J Vijai; AF Vitonis; A von Wachenfeldt; C Walsh; Q (Qing) Wang; S Wang-Gohrke; B Wappenschmidt; M Weischer; JN Weitzel; C Weltens; N Wentzensen; AS Whittemore; LR Wilkens; R Winqvist; AH Wu; XF Wu; HP (Hannah) Yang; D Zaffaroni; MP Zamora; W Zheng; A Ziogas; G Chenevix-Trench; PDP Pharoah; MA Rookus; Maartje Hooning; EL Goode

doi:10.1016/j.ygyno.2015.04.034

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

Antoinette Hollestelle, FH van der Baan, A Berchuck, SE Johnatty, KK Aben, BA Agnarsson, K Aittomaki, E Alducci, IL Andrulis, H Anton-Culver, NN Antonenkova, AC Antoniou, C Apicella, V Arndt, N Arnold, BK Arun, B Arver, A Ashworth, L Baglietto, R BalleineEV Bandera, D Barrowdale, YT Bean, L Beckmann, MW Beckmann, J Benitez, A Berger, R Berger, B Beuselinck, M Bisogna, L Bjorge, C Blomqvist, NV Bogdanova, A Bojesen, SE Bojesen, MK Bolla, B Bonanni, JS Brand, H Brauch, H Brenner, L Brinton, A Brooks-Wilson, F Bruinsma, J Brunet, T Bruning, A Budzilowska, CH Bunker, B Burwinkel, R Butzow, SS Buys, MA Caligo, I Campbell, J Carter, J Chang-Claude, SJ Chanock, KBM Claes, Margriet Collee, LS Cook, FJ Couch, A Cox, D Cramer, SS Cross, JM Cunningham, C Cybulski, K Czene, F Damiola, A Dansonka-Mieszkowska, H Darabi, M de la Hoya, A Defazio, J Dennis, P Devilee, EM Dicks, O Diez, JA Doherty, SM Domchek, CM Dorfling, T Dork, ID Silva, A (Andreas) du Bois, M Dumont, AM Dunning, M (Mercedes) Duran, DF Easton, D Eccles, RP Edwards, H Ehrencrona, B Ejlertsen, AB Ekici, SD Ellis, C Engel, M Eriksson, PA Fasching, L Feliubadalo, J Figueroa, D Flesch-Janys, O Fletcher, A Fontaine, S Fortuzzi, F Fostira, BL Fridley, T Friebel, E Friedman, G Friel, D Frost, J Garber, M Garcia-Closas, SA Gayther, A Gentry-Maharaj, AM Gerdes, GG Giles, R Glasspool, G Glendon, AK Godwin, MT Goodman, M Gore, MH Greene, M Grip, J Gronwald, DG Kaulich, P Guenel, SR Guzman, L Haeberle, CA Haiman, P Hall, SL Halverson, U Hamann, TVO Hansen, P Harter, JM Hartikainen, S Healey, A Hein, F Heitz, BE Henderson, J Herzog, MAT Hildebrandt, CK Bogdan, E Hogdall, FBL Hogervorst, JL Hopper, K Humphreys, T Huzarski, EN Imyanitov, C Isaacs, A Jakubowska, R Janavicius, K Jaworska, A Jensen, UB Jensen, N Johnson, A Jukkola-Vuorinen, M Kabisch, BY Karlan, V Kataja, N Kauff, LE Kelemen, MJ Kerin, LA Kiemeney, SK Kjaer, JA Knight, JP Knol-Bout, I Konstantopoulou, VM Kosma, C Krakstad, V Kristensen, KB Kuchenbaecker, J Kupryjanczyk, Y Laitman, D Lambrechts, S Lambrechts, MC Larson, A Lasa, P Laurent-Puig, C (Conxi) Lazaro, ND Le, L Le Marchand, A Leminen, J Lester, DA Levine, JM Li, D Liang, A Lindblom, N Lindor, J Lissowska, JR Long, KH Lu, J Lubinski, L Lundvall, G Lurie, PL Mai, A Mannermaa, S Margolin, F Mariette, F Marme, John Martens, LFAG Massuger, C Maugard, S Mazoyer, L McGuffog, V McGuire, C McLean, L McNeish, A Meindi, F Menegaux, P Menendez, J Menkiszak, U Menon, AR Mensenkamp, N Miller, RL Milne, F Modugno, M Montagna, KB Moysich, H Muller, AM Mulligan, TA Muranen, SA Narod, KL Nathanson, RB Ness, SL Neuhausen, H Nevanlinna, P Neven, FC Nielsen, SF Nielsen, BG Nordestgaard, RL Nussbaum, K Odunsi, K Offit, E Olah, OI Olopade, JE Olson, SH Olson, JC Oosterwijk, I Orlow, N Orr, S Orsulic, A Osorio, L Ottini, J Paul, CL Pearce, IS Pedersen, B Peissel, T Pejovic, LM Pelttari, J Perkins, J Permuth-Wey, P Peterlongo, J Peto, CM Phelan, KA Phillips, M Piedmonte, MC Pike, R Platte, J Plisiecka-Halasa, EM Poole, B (Bruce) Poppe, K Pylkas, P Radice, SJ Ramus, TR Rebbeck, MWR Reed, G Rennert, HA Risch, M Robson, GC Rodriguez, A Romero, MA Rossing, JH Rothstein, A Rudolph, I Runnebaum, R Salani, HB Salvesen, EJ Sawyer, JM Schildkraut, MK (Marjanka) Schmidt, RK Schmutzler, A Schneeweiss, MJ Schoemaker, MG Schrauder, F Schumacher, I Schwaab, G Scuvera, TA Sellers, G Severi, Caroline Seynaeve, M Shah, M Shrubsole, N Siddiqui, W Sieh, J Simard, CF Singer, OM Sinilnikova, D Smeets, C Sohn, M Soller, H Song, P Soucy, MC Southey, C Stegmaier, D Stoppa-Lyonnet, L Sucheston, A Swerdlow, IL Tangen, MK Tea, MR Teixeira, KL Terry, MB Terry, Marga Thomassen, PJ Thompson, L Tihomirova, M Tischkowitz, AE Toland, RAEM Tollenaar, I Tomlinson, D Torres, T Truong, H Tsimiklis, N Tung, SS Tworoger, JP Tyrer, CM Vachon, LJ (Laura) van 't Veer, AM van Altena, CJ van Asperen, D van den Berg, Ans van den Ouweland, HC van Doom, E Van Nieuwenhuysen, EJ van Rensburg, I Vergote, S Verhoef, RA Vierkant, J Vijai, AF Vitonis, A von Wachenfeldt, C Walsh, Q (Qing) Wang, S Wang-Gohrke, B Wappenschmidt, M Weischer, JN Weitzel, C Weltens, N Wentzensen, AS Whittemore, LR Wilkens, R Winqvist, AH Wu, XF Wu, HP (Hannah) Yang, D Zaffaroni, MP Zamora, W Zheng, A Ziogas, G Chenevix-Trench, PDP Pharoah, MA Rookus, Maartje Hooning, EL Goode

Research output: Contribution to journal › Article › Academic › peer-review

11 Citations (Scopus)

Abstract

Objective. Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. Methods. Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers). Results. We found no association with risk of ovarian cancer (OR = 0.99, 95% CI 0.94-1.04, p = 0.74) or breast cancer (OR = 0.98, 95% CI 0.94-1.01, p = 0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR = 1.09, 95% CI 0.97-1.23, p = 0.14, breast cancer HR = 1.04, 95% CI 0.97-1.12, p = 0.27; BRCA2, ovarian cancer HR = 0.89, 95% CI 0.71-1.13, p = 034, breast cancer HR = 1.06, 95% CI 0.94-1.19, p = 0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR = 0.94, 95% CI 0.83-1.07, p = 0.38), breast cancer (HR = 0.96, 95% CI 0.87-1.06, p = 0.38), and all other previously-reported associations. Conclusions. rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers. (C) 2015 Elsevier Inc. All rights reserved.

Original language	Undefined/Unknown
Pages (from-to)	386-401
Number of pages	16
Journal	Gynecologic Oncology
Volume	141
Issue number	2
DOIs	https://doi.org/10.1016/j.ygyno.2015.04.034
Publication status	Published - 2016

Research programs

EMC MGC-02-96-01
EMC MM-03-52-02-A
EMC MM-03-86-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ygyno.2015.04.034

Cite this

Hollestelle, A., van der Baan, FH., Berchuck, A., Johnatty, SE., Aben, KK., Agnarsson, BA., Aittomaki, K., Alducci, E., Andrulis, IL., Anton-Culver, H., Antonenkova, NN., Antoniou, AC., Apicella, C., Arndt, V., Arnold, N., Arun, BK., Arver, B., Ashworth, A., Baglietto, L., ... Goode, EL. (2016). No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 141(2), 386-401. https://doi.org/10.1016/j.ygyno.2015.04.034

@article{74a37f3895014d41aea62c41547e914d,

title = "No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer",

abstract = "Objective. Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. Methods. Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers). Results. We found no association with risk of ovarian cancer (OR = 0.99, 95% CI 0.94-1.04, p = 0.74) or breast cancer (OR = 0.98, 95% CI 0.94-1.01, p = 0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR = 1.09, 95% CI 0.97-1.23, p = 0.14, breast cancer HR = 1.04, 95% CI 0.97-1.12, p = 0.27; BRCA2, ovarian cancer HR = 0.89, 95% CI 0.71-1.13, p = 034, breast cancer HR = 1.06, 95% CI 0.94-1.19, p = 0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR = 0.94, 95% CI 0.83-1.07, p = 0.38), breast cancer (HR = 0.96, 95% CI 0.87-1.06, p = 0.38), and all other previously-reported associations. Conclusions. rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers. (C) 2015 Elsevier Inc. All rights reserved.",

author = "Antoinette Hollestelle and {van der Baan}, FH and A Berchuck and SE Johnatty and KK Aben and BA Agnarsson and K Aittomaki and E Alducci and IL Andrulis and H Anton-Culver and NN Antonenkova and AC Antoniou and C Apicella and V Arndt and N Arnold and BK Arun and B Arver and A Ashworth and L Baglietto and R Balleine and EV Bandera and D Barrowdale and YT Bean and L Beckmann and MW Beckmann and J Benitez and A Berger and R Berger and B Beuselinck and M Bisogna and L Bjorge and C Blomqvist and NV Bogdanova and A Bojesen and SE Bojesen and MK Bolla and B Bonanni and JS Brand and H Brauch and H Brenner and L Brinton and A Brooks-Wilson and F Bruinsma and J Brunet and T Bruning and A Budzilowska and CH Bunker and B Burwinkel and R Butzow and SS Buys and MA Caligo and I Campbell and J Carter and J Chang-Claude and SJ Chanock and KBM Claes and Margriet Collee and LS Cook and FJ Couch and A Cox and D Cramer and SS Cross and JM Cunningham and C Cybulski and K Czene and F Damiola and A Dansonka-Mieszkowska and H Darabi and {de la Hoya}, M and A Defazio and J Dennis and P Devilee and EM Dicks and O Diez and JA Doherty and SM Domchek and CM Dorfling and T Dork and ID Silva and {du Bois}, {A (Andreas)} and M Dumont and AM Dunning and Duran, {M (Mercedes)} and DF Easton and D Eccles and RP Edwards and H Ehrencrona and B Ejlertsen and AB Ekici and SD Ellis and C Engel and M Eriksson and PA Fasching and L Feliubadalo and J Figueroa and D Flesch-Janys and O Fletcher and A Fontaine and S Fortuzzi and F Fostira and BL Fridley and T Friebel and E Friedman and G Friel and D Frost and J Garber and M Garcia-Closas and SA Gayther and A Gentry-Maharaj and AM Gerdes and GG Giles and R Glasspool and G Glendon and AK Godwin and MT Goodman and M Gore and MH Greene and M Grip and J Gronwald and DG Kaulich and P Guenel and SR Guzman and L Haeberle and CA Haiman and P Hall and SL Halverson and U Hamann and TVO Hansen and P Harter and JM Hartikainen and S Healey and A Hein and F Heitz and BE Henderson and J Herzog and MAT Hildebrandt and CK Bogdan and E Hogdall and FBL Hogervorst and JL Hopper and K Humphreys and T Huzarski and EN Imyanitov and C Isaacs and A Jakubowska and R Janavicius and K Jaworska and A Jensen and UB Jensen and N Johnson and A Jukkola-Vuorinen and M Kabisch and BY Karlan and V Kataja and N Kauff and LE Kelemen and MJ Kerin and LA Kiemeney and SK Kjaer and JA Knight and JP Knol-Bout and I Konstantopoulou and VM Kosma and C Krakstad and V Kristensen and KB Kuchenbaecker and J Kupryjanczyk and Y Laitman and D Lambrechts and S Lambrechts and MC Larson and A Lasa and P Laurent-Puig and Lazaro, {C (Conxi)} and ND Le and {Le Marchand}, L and A Leminen and J Lester and DA Levine and JM Li and D Liang and A Lindblom and N Lindor and J Lissowska and JR Long and KH Lu and J Lubinski and L Lundvall and G Lurie and PL Mai and A Mannermaa and S Margolin and F Mariette and F Marme and John Martens and LFAG Massuger and C Maugard and S Mazoyer and L McGuffog and V McGuire and C McLean and L McNeish and A Meindi and F Menegaux and P Menendez and J Menkiszak and U Menon and AR Mensenkamp and N Miller and RL Milne and F Modugno and M Montagna and KB Moysich and H Muller and AM Mulligan and TA Muranen and SA Narod and KL Nathanson and RB Ness and SL Neuhausen and H Nevanlinna and P Neven and FC Nielsen and SF Nielsen and BG Nordestgaard and RL Nussbaum and K Odunsi and K Offit and E Olah and OI Olopade and JE Olson and SH Olson and JC Oosterwijk and I Orlow and N Orr and S Orsulic and A Osorio and L Ottini and J Paul and CL Pearce and IS Pedersen and B Peissel and T Pejovic and LM Pelttari and J Perkins and J Permuth-Wey and P Peterlongo and J Peto and CM Phelan and KA Phillips and M Piedmonte and MC Pike and R Platte and J Plisiecka-Halasa and EM Poole and Poppe, {B (Bruce)} and K Pylkas and P Radice and SJ Ramus and TR Rebbeck and MWR Reed and G Rennert and HA Risch and M Robson and GC Rodriguez and A Romero and MA Rossing and JH Rothstein and A Rudolph and I Runnebaum and R Salani and HB Salvesen and EJ Sawyer and JM Schildkraut and Schmidt, {MK (Marjanka)} and RK Schmutzler and A Schneeweiss and MJ Schoemaker and MG Schrauder and F Schumacher and I Schwaab and G Scuvera and TA Sellers and G Severi and Caroline Seynaeve and M Shah and M Shrubsole and N Siddiqui and W Sieh and J Simard and CF Singer and OM Sinilnikova and D Smeets and C Sohn and M Soller and H Song and P Soucy and MC Southey and C Stegmaier and D Stoppa-Lyonnet and L Sucheston and A Swerdlow and IL Tangen and MK Tea and MR Teixeira and KL Terry and MB Terry and Marga Thomassen and PJ Thompson and L Tihomirova and M Tischkowitz and AE Toland and RAEM Tollenaar and I Tomlinson and D Torres and T Truong and H Tsimiklis and N Tung and SS Tworoger and JP Tyrer and CM Vachon and {van 't Veer}, {LJ (Laura)} and {van Altena}, AM and {van Asperen}, CJ and {van den Berg}, D and {van den Ouweland}, Ans and {van Doom}, HC and {Van Nieuwenhuysen}, E and {van Rensburg}, EJ and I Vergote and S Verhoef and RA Vierkant and J Vijai and AF Vitonis and {von Wachenfeldt}, A and C Walsh and Wang, {Q (Qing)} and S Wang-Gohrke and B Wappenschmidt and M Weischer and JN Weitzel and C Weltens and N Wentzensen and AS Whittemore and LR Wilkens and R Winqvist and AH Wu and XF Wu and Yang, {HP (Hannah)} and D Zaffaroni and MP Zamora and W Zheng and A Ziogas and G Chenevix-Trench and PDP Pharoah and MA Rookus and Maartje Hooning and EL Goode",

year = "2016",

doi = "10.1016/j.ygyno.2015.04.034",

language = "Undefined/Unknown",

volume = "141",

pages = "386--401",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press",

number = "2",

}

Hollestelle, A, van der Baan, FH, Berchuck, A, Johnatty, SE, Aben, KK, Agnarsson, BA, Aittomaki, K, Alducci, E, Andrulis, IL, Anton-Culver, H, Antonenkova, NN, Antoniou, AC, Apicella, C, Arndt, V, Arnold, N, Arun, BK, Arver, B, Ashworth, A, Baglietto, L, Balleine, R, Bandera, EV, Barrowdale, D, Bean, YT, Beckmann, L, Beckmann, MW, Benitez, J, Berger, A, Berger, R, Beuselinck, B, Bisogna, M, Bjorge, L, Blomqvist, C, Bogdanova, NV, Bojesen, A, Bojesen, SE, Bolla, MK, Bonanni, B, Brand, JS, Brauch, H, Brenner, H, Brinton, L, Brooks-Wilson, A, Bruinsma, F, Brunet, J, Bruning, T, Budzilowska, A, Bunker, CH, Burwinkel, B, Butzow, R, Buys, SS, Caligo, MA, Campbell, I, Carter, J, Chang-Claude, J, Chanock, SJ, Claes, KBM, Collee, M, Cook, LS, Couch, FJ, Cox, A, Cramer, D, Cross, SS, Cunningham, JM, Cybulski, C, Czene, K, Damiola, F, Dansonka-Mieszkowska, A, Darabi, H, de la Hoya, M, Defazio, A, Dennis, J, Devilee, P, Dicks, EM, Diez, O, Doherty, JA, Domchek, SM, Dorfling, CM, Dork, T, Silva, ID, du Bois, A, Dumont, M, Dunning, AM, Duran, M, Easton, DF, Eccles, D, Edwards, RP, Ehrencrona, H, Ejlertsen, B, Ekici, AB, Ellis, SD, Engel, C, Eriksson, M, Fasching, PA, Feliubadalo, L, Figueroa, J, Flesch-Janys, D, Fletcher, O, Fontaine, A, Fortuzzi, S, Fostira, F, Fridley, BL, Friebel, T, Friedman, E, Friel, G, Frost, D, Garber, J, Garcia-Closas, M, Gayther, SA, Gentry-Maharaj, A, Gerdes, AM, Giles, GG, Glasspool, R, Glendon, G, Godwin, AK, Goodman, MT, Gore, M, Greene, MH, Grip, M, Gronwald, J, Kaulich, DG, Guenel, P, Guzman, SR, Haeberle, L, Haiman, CA, Hall, P, Halverson, SL, Hamann, U, Hansen, TVO, Harter, P, Hartikainen, JM, Healey, S, Hein, A, Heitz, F, Henderson, BE, Herzog, J, Hildebrandt, MAT, Bogdan, CK, Hogdall, E, Hogervorst, FBL, Hopper, JL, Humphreys, K, Huzarski, T, Imyanitov, EN, Isaacs, C, Jakubowska, A, Janavicius, R, Jaworska, K, Jensen, A, Jensen, UB, Johnson, N, Jukkola-Vuorinen, A, Kabisch, M, Karlan, BY, Kataja, V, Kauff, N, Kelemen, LE, Kerin, MJ, Kiemeney, LA, Kjaer, SK, Knight, JA, Knol-Bout, JP, Konstantopoulou, I, Kosma, VM, Krakstad, C, Kristensen, V, Kuchenbaecker, KB, Kupryjanczyk, J, Laitman, Y, Lambrechts, D, Lambrechts, S, Larson, MC, Lasa, A, Laurent-Puig, P, Lazaro, C, Le, ND, Le Marchand, L, Leminen, A, Lester, J, Levine, DA, Li, JM, Liang, D, Lindblom, A, Lindor, N, Lissowska, J, Long, JR, Lu, KH, Lubinski, J, Lundvall, L, Lurie, G, Mai, PL, Mannermaa, A, Margolin, S, Mariette, F, Marme, F, Martens, J, Massuger, LFAG, Maugard, C, Mazoyer, S, McGuffog, L, McGuire, V, McLean, C, McNeish, L, Meindi, A, Menegaux, F, Menendez, P, Menkiszak, J, Menon, U, Mensenkamp, AR, Miller, N, Milne, RL, Modugno, F, Montagna, M, Moysich, KB, Muller, H, Mulligan, AM, Muranen, TA, Narod, SA, Nathanson, KL, Ness, RB, Neuhausen, SL, Nevanlinna, H, Neven, P, Nielsen, FC, Nielsen, SF, Nordestgaard, BG, Nussbaum, RL, Odunsi, K, Offit, K, Olah, E, Olopade, OI, Olson, JE, Olson, SH, Oosterwijk, JC, Orlow, I, Orr, N, Orsulic, S, Osorio, A, Ottini, L, Paul, J, Pearce, CL, Pedersen, IS, Peissel, B, Pejovic, T, Pelttari, LM, Perkins, J, Permuth-Wey, J, Peterlongo, P, Peto, J, Phelan, CM, Phillips, KA, Piedmonte, M, Pike, MC, Platte, R, Plisiecka-Halasa, J, Poole, EM, Poppe, B, Pylkas, K, Radice, P, Ramus, SJ, Rebbeck, TR, Reed, MWR, Rennert, G, Risch, HA, Robson, M, Rodriguez, GC, Romero, A, Rossing, MA, Rothstein, JH, Rudolph, A, Runnebaum, I, Salani, R, Salvesen, HB, Sawyer, EJ, Schildkraut, JM, Schmidt, MK, Schmutzler, RK, Schneeweiss, A, Schoemaker, MJ, Schrauder, MG, Schumacher, F, Schwaab, I, Scuvera, G, Sellers, TA, Severi, G, Seynaeve, C, Shah, M, Shrubsole, M, Siddiqui, N, Sieh, W, Simard, J, Singer, CF, Sinilnikova, OM, Smeets, D, Sohn, C, Soller, M, Song, H, Soucy, P, Southey, MC, Stegmaier, C, Stoppa-Lyonnet, D, Sucheston, L, Swerdlow, A, Tangen, IL, Tea, MK, Teixeira, MR, Terry, KL, Terry, MB, Thomassen, M, Thompson, PJ, Tihomirova, L, Tischkowitz, M, Toland, AE, Tollenaar, RAEM, Tomlinson, I, Torres, D, Truong, T, Tsimiklis, H, Tung, N, Tworoger, SS, Tyrer, JP, Vachon, CM, van 't Veer, LJ, van Altena, AM, van Asperen, CJ, van den Berg, D, van den Ouweland, A, van Doom, HC, Van Nieuwenhuysen, E, van Rensburg, EJ, Vergote, I, Verhoef, S, Vierkant, RA, Vijai, J, Vitonis, AF, von Wachenfeldt, A, Walsh, C, Wang, Q, Wang-Gohrke, S, Wappenschmidt, B, Weischer, M, Weitzel, JN, Weltens, C, Wentzensen, N, Whittemore, AS, Wilkens, LR, Winqvist, R, Wu, AH, Wu, XF, Yang, HP, Zaffaroni, D, Zamora, MP, Zheng, W, Ziogas, A, Chenevix-Trench, G, Pharoah, PDP, Rookus, MA, Hooning, M & Goode, EL 2016, 'No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer', Gynecologic Oncology, vol. 141, no. 2, pp. 386-401. https://doi.org/10.1016/j.ygyno.2015.04.034

TY - JOUR

T1 - No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

AU - Hollestelle, Antoinette

AU - van der Baan, FH

AU - Berchuck, A

AU - Johnatty, SE

AU - Aben, KK

AU - Agnarsson, BA

AU - Aittomaki, K

AU - Alducci, E

AU - Andrulis, IL

AU - Anton-Culver, H

AU - Antonenkova, NN

AU - Antoniou, AC

AU - Apicella, C

AU - Arndt, V

AU - Arnold, N

AU - Arun, BK

AU - Arver, B

AU - Ashworth, A

AU - Baglietto, L

AU - Balleine, R

AU - Bandera, EV

AU - Barrowdale, D

AU - Bean, YT

AU - Beckmann, L

AU - Beckmann, MW

AU - Benitez, J

AU - Berger, A

AU - Berger, R

AU - Beuselinck, B

AU - Bisogna, M

AU - Bjorge, L

AU - Blomqvist, C

AU - Bogdanova, NV

AU - Bojesen, A

AU - Bojesen, SE

AU - Bolla, MK

AU - Bonanni, B

AU - Brand, JS

AU - Brauch, H

AU - Brenner, H

AU - Brinton, L

AU - Brooks-Wilson, A

AU - Bruinsma, F

AU - Brunet, J

AU - Bruning, T

AU - Budzilowska, A

AU - Bunker, CH

AU - Burwinkel, B

AU - Butzow, R

AU - Buys, SS

AU - Caligo, MA

AU - Campbell, I

AU - Carter, J

AU - Chang-Claude, J

AU - Chanock, SJ

AU - Claes, KBM

AU - Collee, Margriet

AU - Cook, LS

AU - Couch, FJ

AU - Cox, A

AU - Cramer, D

AU - Cross, SS

AU - Cunningham, JM

AU - Cybulski, C

AU - Czene, K

AU - Damiola, F

AU - Dansonka-Mieszkowska, A

AU - Darabi, H

AU - de la Hoya, M

AU - Defazio, A

AU - Dennis, J

AU - Devilee, P

AU - Dicks, EM

AU - Diez, O

AU - Doherty, JA

AU - Domchek, SM

AU - Dorfling, CM

AU - Dork, T

AU - Silva, ID

AU - du Bois, A (Andreas)

AU - Dumont, M

AU - Dunning, AM

AU - Duran, M (Mercedes)

AU - Easton, DF

AU - Eccles, D

AU - Edwards, RP

AU - Ehrencrona, H

AU - Ejlertsen, B

AU - Ekici, AB

AU - Ellis, SD

AU - Engel, C

AU - Eriksson, M

AU - Fasching, PA

AU - Feliubadalo, L

AU - Figueroa, J

AU - Flesch-Janys, D

AU - Fletcher, O

AU - Fontaine, A

AU - Fortuzzi, S

AU - Fostira, F

AU - Fridley, BL

AU - Friebel, T

AU - Friedman, E

AU - Friel, G

AU - Frost, D

AU - Garber, J

AU - Garcia-Closas, M

AU - Gayther, SA

AU - Gentry-Maharaj, A

AU - Gerdes, AM

AU - Giles, GG

AU - Glasspool, R

AU - Glendon, G

AU - Godwin, AK

AU - Goodman, MT

AU - Gore, M

AU - Greene, MH

AU - Grip, M

AU - Gronwald, J

AU - Kaulich, DG

AU - Guenel, P

AU - Guzman, SR

AU - Haeberle, L

AU - Haiman, CA

AU - Hall, P

AU - Halverson, SL

AU - Hamann, U

AU - Hansen, TVO

AU - Harter, P

AU - Hartikainen, JM

AU - Healey, S

AU - Hein, A

AU - Heitz, F

AU - Henderson, BE

AU - Herzog, J

AU - Hildebrandt, MAT

AU - Bogdan, CK

AU - Hogdall, E

AU - Hogervorst, FBL

AU - Hopper, JL

AU - Humphreys, K

AU - Huzarski, T

AU - Imyanitov, EN

AU - Isaacs, C

AU - Jakubowska, A

AU - Janavicius, R

AU - Jaworska, K

AU - Jensen, A

AU - Jensen, UB

AU - Johnson, N

AU - Jukkola-Vuorinen, A

AU - Kabisch, M

AU - Karlan, BY

AU - Kataja, V

AU - Kauff, N

AU - Kelemen, LE

AU - Kerin, MJ

AU - Kiemeney, LA

AU - Kjaer, SK

AU - Knight, JA

AU - Knol-Bout, JP

AU - Konstantopoulou, I

AU - Kosma, VM

AU - Krakstad, C

AU - Kristensen, V

AU - Kuchenbaecker, KB

AU - Kupryjanczyk, J

AU - Laitman, Y

AU - Lambrechts, D

AU - Lambrechts, S

AU - Larson, MC

AU - Lasa, A

AU - Laurent-Puig, P

AU - Lazaro, C (Conxi)

AU - Le, ND

AU - Le Marchand, L

AU - Leminen, A

AU - Lester, J

AU - Levine, DA

AU - Li, JM

AU - Liang, D

AU - Lindblom, A

AU - Lindor, N

AU - Lissowska, J

AU - Long, JR

AU - Lu, KH

AU - Lubinski, J

AU - Lundvall, L

AU - Lurie, G

AU - Mai, PL

AU - Mannermaa, A

AU - Margolin, S

AU - Mariette, F

AU - Marme, F

AU - Martens, John

AU - Massuger, LFAG

AU - Maugard, C

AU - Mazoyer, S

AU - McGuffog, L

AU - McGuire, V

AU - McLean, C

AU - McNeish, L

AU - Meindi, A

AU - Menegaux, F

AU - Menendez, P

AU - Menkiszak, J

AU - Menon, U

AU - Mensenkamp, AR

AU - Miller, N

AU - Milne, RL

AU - Modugno, F

AU - Montagna, M

AU - Moysich, KB

AU - Muller, H

AU - Mulligan, AM

AU - Muranen, TA

AU - Narod, SA

AU - Nathanson, KL

AU - Ness, RB

AU - Neuhausen, SL

AU - Nevanlinna, H

AU - Neven, P

AU - Nielsen, FC

AU - Nielsen, SF

AU - Nordestgaard, BG

AU - Nussbaum, RL

AU - Odunsi, K

AU - Offit, K

AU - Olah, E

AU - Olopade, OI

AU - Olson, JE

AU - Olson, SH

AU - Oosterwijk, JC

AU - Orlow, I

AU - Orr, N

AU - Orsulic, S

AU - Osorio, A

AU - Ottini, L

AU - Paul, J

AU - Pearce, CL

AU - Pedersen, IS

AU - Peissel, B

AU - Pejovic, T

AU - Pelttari, LM

AU - Perkins, J

AU - Permuth-Wey, J

AU - Peterlongo, P

AU - Peto, J

AU - Phelan, CM

AU - Phillips, KA

AU - Piedmonte, M

AU - Pike, MC

AU - Platte, R

AU - Plisiecka-Halasa, J

AU - Poole, EM

AU - Poppe, B (Bruce)

AU - Pylkas, K

AU - Radice, P

AU - Ramus, SJ

AU - Rebbeck, TR

AU - Reed, MWR

AU - Rennert, G

AU - Risch, HA

AU - Robson, M

AU - Rodriguez, GC

AU - Romero, A

AU - Rossing, MA

AU - Rothstein, JH

AU - Rudolph, A

AU - Runnebaum, I

AU - Salani, R

AU - Salvesen, HB

AU - Sawyer, EJ

AU - Schildkraut, JM

AU - Schmidt, MK (Marjanka)

AU - Schmutzler, RK

AU - Schneeweiss, A

AU - Schoemaker, MJ

AU - Schrauder, MG

AU - Schumacher, F

AU - Schwaab, I

AU - Scuvera, G

AU - Sellers, TA

AU - Severi, G

AU - Seynaeve, Caroline

AU - Shah, M

AU - Shrubsole, M

AU - Siddiqui, N

AU - Sieh, W

AU - Simard, J

AU - Singer, CF

AU - Sinilnikova, OM

AU - Smeets, D

AU - Sohn, C

AU - Soller, M

AU - Song, H

AU - Soucy, P

AU - Southey, MC

AU - Stegmaier, C

AU - Stoppa-Lyonnet, D

AU - Sucheston, L

AU - Swerdlow, A

AU - Tangen, IL

AU - Tea, MK

AU - Teixeira, MR

AU - Terry, KL

AU - Terry, MB

AU - Thomassen, Marga

AU - Thompson, PJ

AU - Tihomirova, L

AU - Tischkowitz, M

AU - Toland, AE

AU - Tollenaar, RAEM

AU - Tomlinson, I

AU - Torres, D

AU - Truong, T

AU - Tsimiklis, H

AU - Tung, N

AU - Tworoger, SS

AU - Tyrer, JP

AU - Vachon, CM

AU - van 't Veer, LJ (Laura)

AU - van Altena, AM

AU - van Asperen, CJ

AU - van den Berg, D

AU - van den Ouweland, Ans

AU - van Doom, HC

AU - Van Nieuwenhuysen, E

AU - van Rensburg, EJ

AU - Vergote, I

AU - Verhoef, S

AU - Vierkant, RA

AU - Vijai, J

AU - Vitonis, AF

AU - von Wachenfeldt, A

AU - Walsh, C

AU - Wang, Q (Qing)

AU - Wang-Gohrke, S

AU - Wappenschmidt, B

AU - Weischer, M

AU - Weitzel, JN

AU - Weltens, C

AU - Wentzensen, N

AU - Whittemore, AS

AU - Wilkens, LR

AU - Winqvist, R

AU - Wu, AH

AU - Wu, XF

AU - Yang, HP (Hannah)

AU - Zaffaroni, D

AU - Zamora, MP

AU - Zheng, W

AU - Ziogas, A

AU - Chenevix-Trench, G

AU - Pharoah, PDP

AU - Rookus, MA

AU - Hooning, Maartje

AU - Goode, EL

PY - 2016

Y1 - 2016

N2 - Objective. Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. Methods. Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers). Results. We found no association with risk of ovarian cancer (OR = 0.99, 95% CI 0.94-1.04, p = 0.74) or breast cancer (OR = 0.98, 95% CI 0.94-1.01, p = 0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR = 1.09, 95% CI 0.97-1.23, p = 0.14, breast cancer HR = 1.04, 95% CI 0.97-1.12, p = 0.27; BRCA2, ovarian cancer HR = 0.89, 95% CI 0.71-1.13, p = 034, breast cancer HR = 1.06, 95% CI 0.94-1.19, p = 0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR = 0.94, 95% CI 0.83-1.07, p = 0.38), breast cancer (HR = 0.96, 95% CI 0.87-1.06, p = 0.38), and all other previously-reported associations. Conclusions. rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers. (C) 2015 Elsevier Inc. All rights reserved.

AB - Objective. Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. Methods. Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers). Results. We found no association with risk of ovarian cancer (OR = 0.99, 95% CI 0.94-1.04, p = 0.74) or breast cancer (OR = 0.98, 95% CI 0.94-1.01, p = 0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR = 1.09, 95% CI 0.97-1.23, p = 0.14, breast cancer HR = 1.04, 95% CI 0.97-1.12, p = 0.27; BRCA2, ovarian cancer HR = 0.89, 95% CI 0.71-1.13, p = 034, breast cancer HR = 1.06, 95% CI 0.94-1.19, p = 0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR = 0.94, 95% CI 0.83-1.07, p = 0.38), breast cancer (HR = 0.96, 95% CI 0.87-1.06, p = 0.38), and all other previously-reported associations. Conclusions. rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers. (C) 2015 Elsevier Inc. All rights reserved.

U2 - 10.1016/j.ygyno.2015.04.034

DO - 10.1016/j.ygyno.2015.04.034

M3 - Article

SN - 0090-8258

VL - 141

SP - 386

EP - 401

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 2

ER -